Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan

Overview

Journal Clin Psychopharmacol Neurosci

Specialty Psychiatry

Date 2021 Oct 25

PMID 34690116

Citations 4

Authors

Masakazu Hatano

Ippei Takeuchi

Kanade Yamashita

Aoi Morita

Kaori Tozawa

Takashi Sakakibara

Genta Hajitsu

Manako Hanya

Shigeki Yamada

Nakao Iwata

Hiroyuki Kamei

Affiliations

Soon will be listed here.

Abstract

Objective: To identify factors affecting adherence to medication, a subjective questionnaire survey was administered to schizophrenia patients regarding the prescribed antipsychotic formulations.

Methods: We evaluated the patients' satisfaction and dissatisfaction with prescribed antipsychotic formulations, and patients answered the Drug Attitude Inventory-10 Questionnaire (DAI-10). Inclusion criteria for patients are as follows: age between 20 and 75 years and taking antipsychotic agents containing the same ingredients and formulations, for at least 1 month.

Results: In total, 301 patients answered the questionnaire survey. Tablets were found to be the most commonly used antipsychotic formulations among schizophrenia patients (n = 174, 57.8%), followed by long-acting injections (LAIs, n = 93, 30.9%). No significant differences in the formulation satisfaction level and DAI-10 scores were observed between all formulations. Formulations, except for LAI, were selected by physicians in more than half of the patients. Patients who answered "Decided by consultation with physicians" had significantly higher satisfaction levels and DAI-10 scores compared to those who answered "Decided by physicians" (4.11 ± 0.77 vs. 3.80 ± 1.00, = 0.0073 and 6.20 ± 3.51 vs. 4.39 ± 4.56, < 0.001, respectively). Satisfaction levels moderately correlated with DAI-10 scores (r = 0.48, < 0.001).

Conclusion: No formulation had a high satisfaction level in all patients, and it is important to be reflect the patients' individual preferences in pharmacotherapy. Shared decision-making in the selection of the formulations is seen to be useful for improving medication adherence.

Citing Articles

Evaluating Adverse Drug Reactions, Their Reporting Rates and Their Impact on Attitudes Toward Pharmacotherapy Among Female Patients with Schizophrenia: Insights and Implications from a Cross-Sectional Study.

Bukic J, Herceg D, Modun D, Krce I, Leskur D, Durdov T Healthcare (Basel). 2025; 12(24.

PMID: 39766022 PMC: 11727682. DOI: 10.3390/healthcare12242595.

Antipsychotic Use: Cross-Sectional Opinion Survey of Psychiatrists in India and United Kingdom.

Sherzad Qadir Z, Kar N, Ball P, Morrissey H Pharmacy (Basel). 2023; 11(5).

PMID: 37888507 PMC: 10609856. DOI: 10.3390/pharmacy11050162.

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia.

Kamei H Medicina (Kaunas). 2022; 58(11).

PMID: 36363541 PMC: 9692600. DOI: 10.3390/medicina58111584.

Treatment Continuation of Asenapine or Olanzapine in Japanese Schizophrenia Patients: A Propensity Score Matched Study.

Matsuzaki H, Hatano M, Iwata M, Yamada S Neuropsychiatr Dis Treat. 2021; 17:3655-3661.

PMID: 34934318 PMC: 8684434. DOI: 10.2147/NDT.S343840.

Patient Factors Influencing Outpatient Retention in Patients with Affective and Anxiety Disorders: A Retrospective Study.

Chang S, Woo Y, Wang S, Lim H, Bahk W Clin Psychopharmacol Neurosci. 2021; 19(3):545-553.

PMID: 34294624 PMC: 8316657. DOI: 10.9758/cpn.2021.19.3.545.

References

Gerrits M, de Greef R, Peeters P . Effect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjects. Biopharm Drug Dispos. 2010; 31(5-6):351-7. DOI: 10.1002/bdd.718. View

Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz W . World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2012; 14(1):2-44. DOI: 10.3109/15622975.2012.739708. View

Fleischhacker W, Oehl M, Hummer M . Factors influencing compliance in schizophrenia patients. J Clin Psychiatry. 2003; 64 Suppl 16:10-3. View

Lacro J, Dunn L, Dolder C, Leckband S, Jeste D . Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002; 63(10):892-909. DOI: 10.4088/jcp.v63n1007. View

Caseiro O, Perez-Iglesias R, Mata I, Martinez-Garcia O, Pelayo-Teran J, Tabares-Seisdedos R . Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res. 2012; 46(8):1099-105. DOI: 10.1016/j.jpsychires.2012.05.001. View

Schiele J, Quinzler R, Klimm H, Pruszydlo M, Haefeli W . Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol. 2012; 69(4):937-48. DOI: 10.1007/s00228-012-1417-0. View

Xia J, Merinder L, Belgamwar M . Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2011; (6):CD002831. PMC: 4170907. DOI: 10.1002/14651858.CD002831.pub2. View

Osterberg L, Blaschke T . Adherence to medication. N Engl J Med. 2005; 353(5):487-97. DOI: 10.1056/NEJMra050100. View

Caroli F, Raymondet P, Izard I, Plas J, Gall B, Delgado A . Opinions of French patients with schizophrenia regarding injectable medication. Patient Prefer Adherence. 2011; 5:165-71. PMC: 3090377. DOI: 10.2147/PPA.S15337. View

10.

Byerly M, Fisher R, Whatley K, Holland R, Varghese F, Carmody T . A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005; 133(2-3):129-33. DOI: 10.1016/j.psychres.2004.11.002. View

11.

Hogan T, Awad A, EASTWOOD R . A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983; 13(1):177-83. DOI: 10.1017/s0033291700050182. View

12.

Hatano M, Kamei H, Kato A, Takeuchi I, Hanya M, Uno J . Assessment of the Latent Adverse Events of Antipsychotic Treatment Using a Subjective Questionnaire in Japanese Patients with Schizophrenia. Clin Psychopharmacol Neurosci. 2017; 15(2):132-137. PMC: 5426495. DOI: 10.9758/cpn.2017.15.2.132. View

13.

Charles C, Gafni A, Whelan T . Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997; 44(5):681-92. DOI: 10.1016/s0277-9536(96)00221-3. View

14.

Witticke D, Seidling H, Klimm H, Haefeli W . Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics. Patient Prefer Adherence. 2012; 6:679-84. PMC: 3461601. DOI: 10.2147/PPA.S35950. View

15.

Kinoshita T, Bai Y, Kim J, Miyake M, Oshima N . Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology (Berl). 2016; 233(14):2663-74. PMC: 4917598. DOI: 10.1007/s00213-016-4295-9. View

16.

Kishimoto T, Nitta M, Borenstein M, Kane J, Correll C . Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013; 74(10):957-65. DOI: 10.4088/JCP.13r08440. View

17.

Shariff Z, Dahmash D, Kirby D, Missaghi S, Rajabi-Siahboomi A, Maidment I . Does the Formulation of Oral Solid Dosage Forms Affect Acceptance and Adherence in Older Patients? A Mixed Methods Systematic Review. J Am Med Dir Assoc. 2020; 21(8):1015-1023.e8. DOI: 10.1016/j.jamda.2020.01.108. View

18.

Robinson D, Woerner M, Alvir J, Bilder R, Goldman R, Geisler S . Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999; 56(3):241-7. DOI: 10.1001/archpsyc.56.3.241. View